Fresenius Medical Care North America Purchases the Remaining Shares of Renaissance Health Care, Inc., and Optimal Renal Care, LLC, and Merges the Two Companies

Business Wire, Jan 16, 2006

LEXINGTON, Mass. -- Fresenius Medical Care North America (FMCNA), a subsidiary of Fresenius Medical Care AG (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced the purchase of the remaining 50% equity shares of Renaissance Health Care, Inc., (Renaissance) from the individual nephrologist shareholders across North America and announces the purchase of the remaining 19% equity shares of Optimal Renal Care, Inc. from the Kaiser Federation. Optimal Renal Care has now been merged into Renaissance Health Care, Inc., and the new company will be called Renaissance Health Care, Inc.

Renaissance now becomes the largest provider of Chronic Kidney Disease Management Services in the world. The merger of the two companies will take advantage of the broad range of expertise and experience of the two companies, while at the same time realizing efficiencies in operating structures and services. The merger combines a complementary customer base and creates a national network of care management services and staff that will allow for a continued expansion of the combined business. This purchase will also allow Fresenius Medical Care to further develop its integrated approach to disease management services and to improve the care for patients with chronic kidney disease.

The corporate headquarters of Renaissance will be located in Lexington, Ma, with call center and operational offices in Broomfield, CO. Robert Farrell, Senior Vice President, Disease Management for FMCNA, President of Fresenius Medical Care Health Plan, and CEO of Renaissance Health Care, Inc. commented, "The purchase of these entities and merger into one operating company expands our ability to improve the care and lives of renal patients and reduces overall expenditures for health care payers. Renaissance will also provide disease management services to the newly-formed Fresenius Medical Care Health Plan, a Medicare Advantage Plan created specifically for end stage renal disease patients. Fresenius Medical Care Health Plan will participate in the Centers for Medicare and Medicaid Services' ESRD Disease Management Demonstration Project. This CMS project is strongly supported by Fresenius Medical Care to bring comprehensive disease management and care coordination services to a broader population of ESRD patients covered under the Medicare Program."

About Renaissance Health Care, Inc.

Renaissance Health Care, Inc. started in 1996, and is the leading provider of Disease Management services for patients with CKD. Renaissance is a National Committee for Quality Assurance (NCQA) accredited renal disease management company providing specialized services to kidney patients. Renaissance has a national network of nurse care managers and an expanding national base of customer contracts that is ready for expansion. The corporate headquarters are located in Lexington, MA. For more information on Renaissance, visit www.usrenal.com. Renaissance Health Care, Inc. is a wholly owned subsidiary of Fresenius Medical Care North America (FMCNA), which is a subsidiary of Fresenius Medical Care AG (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p). For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,300,000 individuals worldwide. Through its network of approximately 1,670 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 130,400 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.